Drospirenone And Ethinyl Estradiol

Introduction Overview

Generic Name

drospirenone and ethinyl estradiol

Brand Name

Yasmin

Dosage Form

Oral tablets

Drug Class

Contraceptives

Pharmacokinetics

Absorption:
Drospirenone and ethinyl estradiol, the combination components of Yasmin, are rapidly and almost completely absorbed following oral administration. Ethinyl estradiol is typically absorbed within 1 to 2 hours, with peak plasma concentrations occurring around 1.5 hours post-dose. Drospirenone reaches peak plasma concentrations approximately 1 to 3 hours after ingestion. Food does not significantly affect the rate or extent of absorption of these components. The high bioavailability of both hormones allows for effective plasma levels to inhibit ovulation and induce contraceptive effects.

Distribution:
Drospirenone is extensively bound to serum albumin (~95%) with negligible binding to sex hormone-binding globulin (SHBG). Ethinyl estradiol binds significantly to serum albumin and induces SHBG synthesis, which may influence the disposition of steroid hormones. Both components distribute into tissues, including reproductive organs. Drospirenone has a volume of distribution approximating 3-5 L/kg, indicating extensive tissue uptake. Ethinyl estradiol has a relatively smaller volume of distribution but is widely distributed. These distribution characteristics facilitate the actions of the hormones on target reproductive tissues.

Metabolism:
Both drospirenone and ethinyl estradiol undergo extensive hepatic metabolism. Drospirenone is metabolized primarily by the cytochrome P450 system, including CYP3A4 enzymes, via hydroxylation and subsequent conjugation into inactive metabolites excreted in urine and feces. Ethinyl estradiol undergoes extensive first-pass metabolism in the liver via hydroxylation (mediated largely by CYP3A4 and CYP2C9) and conjugation pathways such as sulfation and glucuronidation. The metabolism of ethinyl estradiol influences SHBG levels and plays a role in the modulation of hormonal activity.

Elimination:
Elimination of drospirenone occurs via renal and biliary routes, with approximately 47% excreted in urine and 35% in feces as metabolites. The terminal half-life of drospirenone ranges from 30 to 35 hours, supporting once-daily dosing. Ethinyl estradiol is eliminated primarily as conjugates via the feces following enterohepatic recirculation, with an elimination half-life of approximately 15 to 20 hours. The elimination profiles of both components support stable plasma levels, maintaining contraceptive effectiveness during daily administration.

Dosage Forms

Available Dosage Forms:
Yasmin is available as oral tablets formulated for once-daily administration. Each tablet contains a fixed dose combination of drospirenone and ethinyl estradiol.

Dosages for Adults and Adolescents:
The standard dosing regimen for Yasmin consists of one active tablet taken orally at the same time every day for 21 consecutive days, followed by 7 days of inactive placebo tablets or no tablets, during which withdrawal bleeding occurs. Each active tablet contains 3 mg of drospirenone and 0.03 mg of ethinyl estradiol. This regimen provides consistent hormone levels to inhibit ovulation effectively. Initiation instructions include starting on the first day of menstruation or the first Sunday following the onset of menstruation.

Specific Patient Populations:
Yasmin is intended for use in adult and adolescent females who require contraception. It is not recommended for use in breastfeeding women due to potential effects on milk production and hormone transfer to the infant. Caution is advised in patients with hepatic or renal impairment, as metabolism and clearance of components may be affected. Dosing adjustments are not typically required but clinical monitoring is essential. Yasmin is contraindicated in patients with cardiovascular risk factors, uncontrolled hypertension, or thrombotic disorders.

Detailed Dosage Information:
- Oral tablets containing drospirenone 3 mg and ethinyl estradiol 0.03 mg.
- Taken once daily, preferably at the same time each day.
- 21 active hormone pills followed by 7 inactive pills (or 7-day tablet-free interval).
- If a dose is missed, a specific protocol is followed to reduce the risk of pregnancy, including taking missed pills as soon as remembered and using backup contraception if multiple pills are missed.
- No dosage change is normally required based on age or weight; however, monitoring for adverse reactions is important.

Mechanism Of Action

Yasmin combines drospirenone, a synthetic progestin with anti-mineralocorticoid and anti-androgenic properties, and ethinyl estradiol, a synthetic estrogen analogue. The contraceptive effect of Yasmin is primarily achieved by suppression of ovulation through negative feedback mechanisms on the hypothalamic-pituitary-ovarian axis. Ethinyl estradiol suppresses follicle-stimulating hormone (FSH) secretion, thereby inhibiting follicular development, while drospirenone suppresses luteinizing hormone (LH) surge, preventing ovulation.

In addition to ovulation suppression, drospirenone thickens cervical mucus, creating a barrier that impedes sperm penetration and migration into the uterus. It also alters the endometrial lining, rendering it less receptive to implantation of a fertilized egg. The combined hormonal effects create multiple contraceptive barriers, significantly reducing the likelihood of fertilization and pregnancy.

Drospirenone’s anti-mineralocorticoid activity counterbalances estrogen-induced fluid retention by antagonizing aldosterone receptors in the renal distal tubules. This property contributes to reduced weight gain and edema commonly associated with estrogen-containing contraceptives. Furthermore, its anti-androgenic effects may reduce acne and sebaceous gland activity.

Comparatively, Yasmin differs from other combined oral contraceptives by virtue of drospirenone’s additional pharmacologic effects, including potassium-sparing properties and favorable impact on lipid profiles. Clinical studies demonstrate Yasmin’s efficacy in preventing pregnancy with a low incidence of adverse cardiovascular effects when used in appropriate populations.

Pharmacological Actions

Combined estrogen-progestin hormonal contraception that prevents ovulation.
Suppression of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion by pituitary gland.
Thickening of cervical mucus to inhibit sperm penetration.
Alteration of endometrial lining to prevent implantation of fertilized egg.
Anti-mineralocorticoid effect reducing fluid retention and weight gain.
Anti-androgenic activity reducing acne and sebaceous gland activity.
Regulation of menstrual cycles and reduction of menstrual bleeding.
Potential to favorably modify lipid metabolism and reduce androgen-related symptoms.
Provides contraception through multiple mechanisms to ensure high efficacy.
Suppression of ovulation by combined hormonal feedback on hypothalamic-pituitary axis.
Reduction of premenstrual symptoms through hormonal stabilization.
Potassium-sparing effect that requires monitoring in susceptible patients.
Influence on SHBG levels to modulate circulating sex hormone activity.
Neurological modulation possibly reducing migraine frequency in select patients.

Therapeutic Or Clinical Uses

Prevention of pregnancy as a combined oral contraceptive.
Regulation of menstrual cycles in women requiring contraception.
Treatment of acne vulgaris associated with androgenic etiology (off-label or related formulations).
Management of premenstrual dysphoric disorder symptoms (in related drospirenone/ethinyl estradiol formulations).
Suppression of ovulation for management of hormonal imbalances.
Reduction in ovarian cyst formation in reproductive-age women.
Potential therapeutic option for mild hyperandrogenic symptoms due to anti-androgenic effects.
Contraception in women seeking an oral hormonal method with lower risk of weight gain.
Prevention of endometrial hyperplasia via regulation of endometrial proliferation.
Alternative hormonal contraception for patients intolerant to other progestins.
Support in reducing menstrual bleeding and dysmenorrhea symptoms.
Contraceptive choice for women desiring once-daily, oral combined hormone therapy.
Use in sexually active women requiring pregnancy prevention with added benefits of mineralocorticoid antagonism.
Option for women with concerns about fluid retention from other contraceptives.
Alternative combined oral contraceptive compatible with certain lipid profile requirements.

Side Or Adverse Effects

Nausea and occasional vomiting, particularly during initial treatment phases.
Breast tenderness or enlargement resulting from hormonal changes.
Headache, which can vary from mild to severe, including changes in migraine patterns.
Mood changes including irritability, depression, or mood swings.
Weight gain potentially related to fluid retention or appetite changes.
Changes in menstrual bleeding patterns such as breakthrough bleeding or spotting.
Decreased libido or changes in sexual desire.
Increased risk of venous thromboembolism including deep vein thrombosis and pulmonary embolism.
Elevated blood pressure in susceptible individuals.
Potential for hyperkalemia due to drospirenone’s potassium-sparing effects.
Allergic reactions including rash, hives, or angioedema though rare.
Fatigue or tiredness possibly related to hormonal shifts.
Gastrointestinal disturbances including abdominal pain or cramps.
Risk of cardiovascular events such as stroke or heart attack, especially in smokers over 35 years old.
Possible liver enzyme alterations or rare liver dysfunction.

Precautions

Assess cardiovascular risk factors before prescribing due to thromboembolism risk.
Avoid use in women who smoke and are over 35 years of age.
Monitor blood pressure regularly during treatment.
Use caution in patients with a history of migraine, especially with aura.
Evaluate potassium levels in patients with renal impairment or on potassium-sparing diuretics.
Delay use for at least 4 weeks postpartum or after miscarriage/abortion due to clot risk.
Do not initiate during undiagnosed vaginal bleeding; investigate cause first.
Screen patients for liver disease or tumors prior to initiation.
Caution when administered concomitantly with drugs that induce hepatic enzymes.
Avoid use in patients with adrenal gland disorders or kidney disease.
Discontinue if pregnancy occurs or is suspected.
Educate patients on the importance of adherence to dosing schedule to reduce risk of pregnancy.
Warn patients that Yasmin does not protect against sexually transmitted infections.
Consider alternative contraception in patients with a history of depression worsening with hormones.
Advise patients about signs and symptoms of thrombotic events requiring immediate medical attention.

Warnings

Do not use if pregnant or suspect pregnancy; contraindicated in pregnancy.
Increased risk of serious cardiovascular events including blood clots, stroke, and heart attack.
Use contraindicated in presence of uncontrolled hypertension or significant cardiovascular disease.
Avoid in patients with a history of thromboembolic disorders or hereditary clotting abnormalities.
Stop use prior to major surgery or prolonged immobilization due to clot risk.
Smoking markedly increases risk of cardiovascular adverse events; avoid if over 35 years and smoker.
Potential for serious liver problems including jaundice, cholestasis, or liver tumors.
Possible exacerbation of migraine headaches, particularly with aura or neurological symptoms.
May cause changes in mood including depression; monitor and manage accordingly.
Use is contraindicated in patients with hormone-sensitive cancers such as breast or endometrial cancer.
Concurrent use with certain hepatitis C medications (ombitasvir/paritaprevir/ritonavir) is contraindicated.
Increase vigilance in patients with renal impairment due to drospirenone’s mineralocorticoid effects.
Report any signs of allergic reaction immediately.
Monitor for unusual vaginal bleeding that could indicate serious underlying conditions.
Not to be used during breastfeeding due to potential neonatal effects and inhibition of milk production.

Contraindication

Known or suspected pregnancy.
History of or current thromboembolic disorders including deep vein thrombosis or pulmonary embolism.
Severe uncontrolled hypertension.
Adrenal gland disorders such as Addison’s disease.
Kidney disease with impaired function or untreated renal insufficiency.
Liver disease or liver tumors, including hepatic adenomas or carcinoma.
History of hormone-dependent cancers, including breast cancer or endometrial cancer.
Undiagnosed abnormal vaginal bleeding.
Migraines with focal neurological symptoms, especially in women older than 35.
Current or past history of stroke or myocardial infarction.
Known hypersensitivity to drospirenone, ethinyl estradiol, or any tablet component.
Smoking combined with age above 35 years.
Concurrent use of hepatitis C medications containing ombitasvir/paritaprevir/ritonavir (e.g., Technivie).
Severe depression that could worsen with hormonal therapy.
Porphyria or other rare hereditary disorders affecting hormone metabolism.

Drug Interactions

Drugs that induce hepatic enzymes (e.g., rifampin, phenytoin, carbamazepine) can reduce effectiveness by increasing hormonal metabolism.
Concomitant use with certain hepatitis C antiviral agents like ombitasvir/paritaprevir/ritonavir is contraindicated due to potential liver toxicity.
Use with antibiotics such as rifampin may decrease contraceptive efficacy by altering gut flora or hepatic metabolism.
Anticonvulsants such as phenobarbital may reduce plasma concentrations of contraceptive hormones.
St. John’s Wort can induce CYP3A4 and reduce the effectiveness of Yasmin.
Use caution with other potassium-sparing drugs or potassium supplements due to risk of hyperkalemia.
Co-administration with other hormonal therapies or contraceptives increases risk of adverse effects.
Certain antiretrovirals may alter hormonal levels by induction or inhibition of liver enzymes.
Drugs affecting gastrointestinal motility or absorption may reduce contraceptive efficacy.
Monitoring required when used with systemic corticosteroids due to potential interaction effects.
CYP3A4 inhibitors can increase hormone concentrations, potentially increasing side effects.
Concurrent use with warfarin may interfere with anticoagulation efficacy.
Alcohol and smoking can affect drug metabolism and clot risk; advise avoidance or moderation.
Herbal supplements other than St. John's Wort should be considered for possible interactions.
Adjust monitoring and counseling necessary during concurrent use of interacting medications to ensure contraceptive efficacy.

Preparations Of The Drug

Yasmin identified as combination oral contraceptive tablets each containing drospirenone 3 mg and ethinyl estradiol 0.03 mg.
Commercially available as blister packs containing 21 active hormone tablets plus 7 inert placebos or 28 active tablets.
Packaged for once-daily oral administration with clear dosing instructions.
Available predominantly as film-coated oral tablets for ease of ingestion and tolerability.
Generic forms may be available containing identical dosages of active ingredients.
Tablets contain inactive ingredients such as lactose monohydrate, povidone, magnesium stearate, and film-coating agents.
Provided in prescription-only formulations requiring doctor supervision and follow-up.
Supplied in unit-dose packaging to maintain stability and protect from moisture.
Storage recommended at room temperature away from excessive heat and humidity to preserve potency.
Patient information leaflets include detailed instructions to promote adherence and inform about risks.
Available in combination packs suitable for continuous or cyclic contraceptive regimens.
May be included in multipack birth control supplies to cover extended periods of contraception.
Prescription strength standardized to maintain consistent dosing across different production batches.
Some formulations include placebo tablets to maintain pill-taking habit and monitor adherence.
Formulations contain drospirenone and ethinyl estradiol confirmed through rigorous quality control standards.